Physician profile
Lewis S Blevins
NPI 1295822393
$165,876.89
in general payments reported to CMS, 2019-2025
13 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $22K · 2021: $41K · 2022: $26K · 2023: $26K · 2024: $13K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $32K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $7,396 · Consulting Fee: $5,313 · Food and Beverage: $1,869 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $31,984.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,791.00 |
| Travel and Lodging | $7,396.14 |
| Consulting Fee | $5,312.50 |
| Food and Beverage | $1,869.40 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $98,799.13 | 2019-2025 | Korlym |
| Recordati_rare_diseases_inc. | $29,849.20 | 2021-2025 | Isturisa |
| Novo Nordisk INC | $15,096.08 | 2019-2024 | Sogroya |
| Genentech USA, INC. | $7,987.50 | 2019-2021 | |
| Chiasma, INC. | $5,710.00 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $2,578.50 | 2025 | |
| Biomarin Pharmaceutical INC. | $2,457.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $1,530.83 | 2019-2020 | |
| Pfizer INC. | $1,283.44 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $281.56 | 2024-2025 | Recorlev |
| Chiesi USA, INC. | $113.61 | 2023 | |
| Ascendis Pharma Endocrinology INC | $99.44 | 2025 | Skytrofa |
| Strongbridge US INC. | $90.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Blevins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.